Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of Remdesivir to NHS hospitals; and if he will make a statement.

Remdesivir has been available to National Health Service patients with COVID-19 as part of clinical trials and, most recently, through the Early Access to Medicines Scheme (EAMS). EAMS aims to give patients with life-threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation where there is a clear unmet medical need. Eligible NHS patients will continue to benefit from treatment with remdesivir and the NHS has sufficient stock of remdesivir for patients who need it.